What Erlonat Capsule is?
Erlonat tablets is a specific tyrosine kinase inhibitor, indicated for the treatment of Pancreatic Cancer and Non-Small Cell Lung Cancer (NSCLC).
- Specifically, it is used to treat locally advanced as well as metastatic non-small lung cancer after the failure of at least one prior chemotherapy regimen.
- It is also used for the Non-Small Cell Lung Cancer either with EGFR exon 21 or EGFR exon 19 deletion substitution mutation which has spread to other parts of the body.
- Patients with locally advanced as well as metastatic non-small lung cancer may take this medication with the combination of gemcitabine as a first-line treatment.
What Erlotinib is?
Erlotinib in unresectable non-small cell lung cancer when added to chemotherapy improves overall survival by 19%, and improved progression-free survival (PFS) by 29%, when compared to chemotherapy alone. The U.S. Food and Drug Administration (FDA) approved erlotinib for the treatment of locally advanced or metastatic non-small cell lung cancer that has failed at least one prior chemotherapy regimen.]
In November 2005, the FDA approved erlotinib in combination with gemcitabine for treatment of locally advanced, unresectable, or metastatic pancreatic cancer.